Author

A. Vasciaveo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

M. M. Shen· 3 shared A. Califano· 2 shared C. Abate-Shen· 2 shared M. A. Rubin· 2 shared M. Zou· 2 shared A. Alaimo· 1 shared A. Lunardi· 1 shared A. Mitrofanova· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. M. Shen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer

D. De Felice, A. Alaimo, D. Bressan, S. Genovesi, E. Marmocchi, N. Annesi, G. Beccaceci, D. Dalfovo, F. Cutrupi, V. Foletto, M. Lorenzoni, F. Gandolfi, S. Kannan, C. S. Verma, A. Vasciaveo, , A. Lunardi

This study shows RA signaling promotes luminal identity in prostate progenitors through Foxa1, and identifies a loss-of-function mutation in Foxa1 linked to prostate cancer dedifferentiation.

bioRxiv · Mar 6, 2024Cancer Biology

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

J. J. Li, A. Vasciaveo, D. Karagiannis, Z. Sun, X. Chen, F. Socciarelli, Z. Frankenstein, M. Zou, T. Pannellini, Y. Chen, K. Gardner, B. D. Robinson, J. de Bono, C. Abate-Shen, M. A. Rubin, , M. M. Shen

This study identifies NSD2 as a key driver of lineage plasticity and castration-resistance in neuroendocrine prostate cancer, showing its inhibition can restore sensitivity to AR inhibitors.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

OncoLoop: A network-based precision cancer medicine framework

A. Vasciaveo, M. Zou, J. M. Arriaga, F. Geraldes de Almeida, E. F. Douglass, M. Shibata, A. Rodriguez-Calero, S. de Brot, A. Mitrofanova, C. W. Chua, C. Karan, R. Realubit, S. Y. Pampou, J. Y. Kim, E. Corey, , C. Abate-Shen

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

bioRxiv · Feb 11, 2022Cancer Biology